Cannabidiol Use in Refractory Epilepsy

Marcia L. Buck, PharmD, FCCP, FPPAG, BCPPS


Pediatr Pharm. 2018;24(11) 

In This Article


The FDA approval of CBD oral solution provides another new option for the treatment of refractory seizures in children and adults with LGS and Dravet syndrome. Early research suggests that CBD may also be of value in patients with refractory seizures associated with brain tumors, genetic syndromes, or FIRES. While CBD is generally well tolerated, patients should be closely monitored for adverse effects, including hepatotoxicity, and any new medications should be evaluated for potential interactions with CBD prior to initiation.